Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 NMK36 (fluciclovine 18F) PET/CT for detecting regional lymph node metastasis in prostate cancer
jRCT2080222656Phase 2Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Nov 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoint: Diagnostic sensitivity for detecting metastatic regional lymph nodes (5 mm to <10 mm minor axis). Started Nov 2014; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080222656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222656.